Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
Abstract Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease.
Main Authors: | Hninyee Win, Krisstina Gowin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.3302 |
Similar Items
-
Scleromyxedema: A Case Report and Review of the Literature
by: Mohamed Allam, et al.
Published: (2013-06-01) -
Severe cutaneous scleromyxedema treated by lenalidomide
by: Théo Brochet, et al.
Published: (2023-09-01) -
Scleromyxedema without Paraproteinemia: Treatment with Thalidomide and Prednisolone
by: Sara Saniee, et al.
Published: (2016-11-01) -
A rare case of tumoral scleromyxedema
by: Ali Sadeghinia, et al.
Published: (2020-01-01) -
Plasma cell myeloma masquerading as scleromyxedema
by: Varun Victor, et al.
Published: (2019-01-01)